Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 4D-150 (Primary) ; Aflibercept
  • Indications Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms 4FRONT-2
  • Sponsors 4D Molecular Therapeutics

Most Recent Events

  • 10 Nov 2025 According to a 4D Molecular Therapeutics media release, enrollment remains on track to be completed in H2 2026, with 52-week topline data expected in H2 2027
  • 30 Oct 2025 According to a 4D Molecular Therapeutics media release, APAC clinical sites are expected to open by end of year, with Japan sites expected to open in January 2026.
  • 02 Jul 2025 According to 4DMT media release, the company announced the acceleration of the 4D-150 4FRONT Phase 3 program in wet AMD.he Company also has streamlined operations to offset additional expenses expected based on the accelerated timelines for the 4FRONT clinical trials and BLA preparation, which supports the Company's cash runway into 2028, as previously guided.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top